LONDON: Open Orphan, a European-focussed, rare and orphan drug consulting services platform, has signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform. The platform is expected to be completed and rolled out in Q1 2020.

The five companies signed up to the Genomic Health DataBANK platform will ensure the database is ‘fit-for-purpose’ from a pharmaceutical and data analysis perspective ahead of the first patient data upload. This builds upon our previously announced collaboration with Empiric Logic who will work with the Company to complete the platform.

In conjunction, Open Orphan is working to finalise early adopter agreements with several Patient Advocacy Groups, who will make their patients aware of Open Orphan’s Genomic Database. The Company hopes to make an announcement on this front shortly.

These strategic agreements will allow Open Orphan to deliver on its objective to build Europe’s first rare disease, advocacy-led genomic database which will empower patients to directly drive research into their own respective disease.

Maurice Treacy, Chief Commercial Officer of Open Orphan commented: “We are very excited to be working with these leading pharmaceutical and biotechnology companies on our market leading DataBANK. The Genomic Health DataBANK, which makes extensive use of AI tools, is an innovative research tool for pharmaceutical companies, and we are excited by its potential when launched in early 2020. We believe the DataBANK can ignite research for new diagnostic tools and therapeutic products for rare disease patients.”